[HTML][HTML] Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

E Mamessier, A Sylvain, ML Thibult… - The Journal of …, 2011 - Am Soc Clin Investig
E Mamessier, A Sylvain, ML Thibult, G Houvenaeghel, J Jacquemier, R Castellano…
The Journal of clinical investigation, 2011Am Soc Clin Investig
NK cells are a major component of the antitumor immune response and are involved in
controlling tumor progression and metastases in animal models. Here, we show that
dysfunction of these cells accompanies human breast tumor progression. We characterized
human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-
NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from
the peripheral blood of healthy donors and normal breast tissue were used as controls. With …
NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we show that dysfunction of these cells accompanies human breast tumor progression. We characterized human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from the peripheral blood of healthy donors and normal breast tissue were used as controls. With disease progression, we found that expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM-1, and CD16) decreased while expression of inhibitory receptors (such as NKG2A) increased and that this correlated with decreased NK cell function, most notably cytotoxicity. Importantly, Ti-NK cells had more pronounced impairment of their cytotoxic potential than p-NK cells. We also identified several stroma-derived factors, including TGF-β1, involved in tumor-induced reduction of normal NK cell function. Our data therefore show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity. This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity.
The Journal of Clinical Investigation